As shown in Figure 6, A–D, compared with control treatment, treatment with CCL8 triggered the migration of HepG2 hepatoma cells, substantially increased their levels of vimentin and SNAI1 expression, and downregulated their levels of E-cadherin expression. The gene discussed is CCL8; the disease is hepatocellular carcinoma.